NEI Research News

A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab).

A study funded by the National Eye Institute (NEI), part of the National Institutes of Health, has shown that uncorrected farsightedness (hyperopia) in preschool children is associated with significantly worse performance on a test of early literacy.

An analysis funded by the National Eye Institute (NEI), part of the National Institutes of Health, has identified three genes that contribute to the most common type of glaucoma.

Our eyes are especially demanding when it comes to energy: Along with our brain, they require a substantial amount of power to keep them functioning and healthy.

As we age, proteins in the lenses of our eyes start misbehaving: They unfold and congregate in clusters that block, scatter and distort light as it passes through the lens.

With Glaucoma Awareness Month in January, it’s a good time to think about scheduling a comprehensive dilated eye exam, especially if you’re at risk for glaucoma.

An international study of about 43,000 people has significantly expanded the number of genetic factors known to play a role in age-related macular degeneration (AMD), a leading cause of vision loss among people age 50 and older.

As part of the National Robotics Initiative (NRI), the National Institutes of Health announced that it will fund the development of three innovative co-robots—robots that work cooperatively with people.

This National Diabetes Month, there is some good news for people with eye complications from diabetes.

A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy.